Silver Nanoparticles for the Therapy of Tuberculosis

Alexandru-Flaviu Tăbăran,1,2,* Cristian Tudor Matea,2,* Teodora Mocan,2,3,* Alexandra Tăbăran,4,* Marian Mihaiu,4,* Cornel Iancu,2,5,* Lucian Mocan2,3,* 1Department of Pathology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; 2Department of Nanomedicine, Regional...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tăbăran AF, Matea CT, Mocan T, Tăbăran A, Mihaiu M, Iancu C, Mocan L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	nanoparticles antimycobacterial mycobacterium tuberculosis macrophage granuloma Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/70c3f6935c834c0eada15e20cdd7b3f6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70c3f6935c834c0eada15e20cdd7b3f6
record_format	dspace
spelling	oai:doaj.org-article:70c3f6935c834c0eada15e20cdd7b3f62021-12-02T05:21:03ZSilver Nanoparticles for the Therapy of Tuberculosis1178-2013https://doaj.org/article/70c3f6935c834c0eada15e20cdd7b3f62020-03-01T00:00:00Zhttps://www.dovepress.com/silver-nanoparticles-for-the-therapy-of-tuberculosis-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Alexandru-Flaviu Tăbăran,1,2,* Cristian Tudor Matea,2,* Teodora Mocan,2,3,* Alexandra Tăbăran,4,* Marian Mihaiu,4,* Cornel Iancu,2,5,* Lucian Mocan2,3,* 1Department of Pathology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; 2Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; 3Department of Physiology, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 4Department of Public Health and Food Hygiene, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; 5Third Surgery Department, University of Medicine and Pharmacy, Cluj-Napoca, Romania*These authors contributed equally to this workCorrespondence: Teodora MocanDepartment of Physiology, University of Medicine and Pharmacy Cluj-Napoca, Romania 1 Clinicilor Street, Cluj-Napoca 40006, RomaniaTel +40 264 598575Fax +40 264 599814Email Teodora.mocan@umfcluj.roAbstract: Rapid emergence of aggressive, multidrug-resistant Mycobacteria strain represents the main cause of the current antimycobacterial-drug crisis and status of tuberculosis (TB) as a major global health problem. The relatively low-output of newly approved antibiotics contributes to the current orientation of research towards alternative antibacterial molecules such as advanced materials. Nanotechnology and nanoparticle research offers several exciting new-concepts and strategies which may prove to be valuable tools in improving the TB therapy. A new paradigm in antituberculous therapy using silver nanoparticles has the potential to overcome the medical limitations imposed in TB treatment by the drug resistance which is commonly reported for most of the current organic antibiotics. There is no doubt that AgNPs are promising future therapeutics for the medication of mycobacterial-induced diseases but the viability of this complementary strategy depends on overcoming several critical therapeutic issues as, poor delivery, variable intramacrophagic antimycobacterial efficiency, and residual toxicity. In this paper, we provide an overview of the pathology of mycobacterial-induced diseases, andhighlight the advantages and limitations of silver nanoparticles (AgNPs) in TB treatment.Keywords: nanoparticles, antimycobacterial, Mycobacterium, tuberculosis, macrophage, granulomaTăbăran AFMatea CTMocan TTăbăran AMihaiu MIancu CMocan LDove Medical PressarticlenanoparticlesantimycobacterialmycobacteriumtuberculosismacrophagegranulomaMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 2231-2258 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanoparticles antimycobacterial mycobacterium tuberculosis macrophage granuloma Medicine (General) R5-920
spellingShingle	nanoparticles antimycobacterial mycobacterium tuberculosis macrophage granuloma Medicine (General) R5-920 Tăbăran AF Matea CT Mocan T Tăbăran A Mihaiu M Iancu C Mocan L Silver Nanoparticles for the Therapy of Tuberculosis
description	Alexandru-Flaviu Tăbăran,1,2,* Cristian Tudor Matea,2,* Teodora Mocan,2,3,* Alexandra Tăbăran,4,* Marian Mihaiu,4,* Cornel Iancu,2,5,* Lucian Mocan2,3,* 1Department of Pathology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; 2Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; 3Department of Physiology, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 4Department of Public Health and Food Hygiene, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; 5Third Surgery Department, University of Medicine and Pharmacy, Cluj-Napoca, Romania*These authors contributed equally to this workCorrespondence: Teodora MocanDepartment of Physiology, University of Medicine and Pharmacy Cluj-Napoca, Romania 1 Clinicilor Street, Cluj-Napoca 40006, RomaniaTel +40 264 598575Fax +40 264 599814Email Teodora.mocan@umfcluj.roAbstract: Rapid emergence of aggressive, multidrug-resistant Mycobacteria strain represents the main cause of the current antimycobacterial-drug crisis and status of tuberculosis (TB) as a major global health problem. The relatively low-output of newly approved antibiotics contributes to the current orientation of research towards alternative antibacterial molecules such as advanced materials. Nanotechnology and nanoparticle research offers several exciting new-concepts and strategies which may prove to be valuable tools in improving the TB therapy. A new paradigm in antituberculous therapy using silver nanoparticles has the potential to overcome the medical limitations imposed in TB treatment by the drug resistance which is commonly reported for most of the current organic antibiotics. There is no doubt that AgNPs are promising future therapeutics for the medication of mycobacterial-induced diseases but the viability of this complementary strategy depends on overcoming several critical therapeutic issues as, poor delivery, variable intramacrophagic antimycobacterial efficiency, and residual toxicity. In this paper, we provide an overview of the pathology of mycobacterial-induced diseases, andhighlight the advantages and limitations of silver nanoparticles (AgNPs) in TB treatment.Keywords: nanoparticles, antimycobacterial, Mycobacterium, tuberculosis, macrophage, granuloma
format	article
author	Tăbăran AF Matea CT Mocan T Tăbăran A Mihaiu M Iancu C Mocan L
author_facet	Tăbăran AF Matea CT Mocan T Tăbăran A Mihaiu M Iancu C Mocan L
author_sort	Tăbăran AF
title	Silver Nanoparticles for the Therapy of Tuberculosis
title_short	Silver Nanoparticles for the Therapy of Tuberculosis
title_full	Silver Nanoparticles for the Therapy of Tuberculosis
title_fullStr	Silver Nanoparticles for the Therapy of Tuberculosis
title_full_unstemmed	Silver Nanoparticles for the Therapy of Tuberculosis
title_sort	silver nanoparticles for the therapy of tuberculosis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/70c3f6935c834c0eada15e20cdd7b3f6
work_keys_str_mv	AT tabaranaf silvernanoparticlesforthetherapyoftuberculosis AT mateact silvernanoparticlesforthetherapyoftuberculosis AT mocant silvernanoparticlesforthetherapyoftuberculosis AT tabarana silvernanoparticlesforthetherapyoftuberculosis AT mihaium silvernanoparticlesforthetherapyoftuberculosis AT iancuc silvernanoparticlesforthetherapyoftuberculosis AT mocanl silvernanoparticlesforthetherapyoftuberculosis
_version_	1718400420093624320

Silver Nanoparticles for the Therapy of Tuberculosis

Ejemplares similares